INTERVIEW: Behind The Scenes Of Skyepharma's Financial Phoenix And Merger
Executive Summary
Skyepharma's outgoing CEO Peter Grant, has been masterminding the company's return to profitability for a decade. He looks back on how he negotiated pharma's financial waters and how that led to the company's merger with UK competitor Vectura.
You may also be interested in...
Vectura, Skyepharma To Form World Respiratory Leader
A UK-based global leader in respiratory therapies will be created by Vectura Group PLC's planned purchase of SkyePharma PLC in a friendly, all-stock deal to forge a combined group with estimated market capitalization of just over £1bn, joint sales of £153.9m and profits of around £50.5m.
SkyePharma Thoughts Turn To M&A And In-House Research After Financial Turnaround
With increasing revenues and profits the UK drug delivery firm SkyePharma could only dream of some years ago, CEO Peter Grant says he will consider investing in internal research and external M&A opportunities, in a measured way, to build a long-term product pipeline.
Another top exec leaves AstraZeneca
A second top AstraZeneca executive is to leave the company in as many weeks. James Ward-Lilley, currently head of AstraZeneca's respiratory, inflammation and autoimmunity product and portfolio strategy, and a 28-year veteran of the company, is to become CEO of Vectura, a small UK firm focused on lung disease.